Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peptides | 18 | 2024 | 357 | 3.460 |
Why?
|
| Histocompatibility Antigens Class I | 7 | 2022 | 32 | 1.400 |
Why?
|
| Proteins | 5 | 2023 | 383 | 1.160 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 378 | 1.130 |
Why?
|
| Receptors, Antigen, T-Cell | 5 | 2024 | 66 | 1.110 |
Why?
|
| Neoplasms | 5 | 2023 | 1341 | 1.090 |
Why?
|
| Models, Molecular | 11 | 2020 | 875 | 0.810 |
Why?
|
| Cross Reactions | 5 | 2019 | 86 | 0.730 |
Why?
|
| Major Histocompatibility Complex | 4 | 2024 | 27 | 0.650 |
Why?
|
| Protein Binding | 12 | 2024 | 1076 | 0.640 |
Why?
|
| HLA Antigens | 2 | 2022 | 27 | 0.600 |
Why?
|
| Epitopes | 6 | 2024 | 155 | 0.570 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2022 | 181 | 0.480 |
Why?
|
| Software | 1 | 2017 | 234 | 0.480 |
Why?
|
| Hepacivirus | 2 | 2015 | 73 | 0.450 |
Why?
|
| Nelfinavir | 1 | 2014 | 4 | 0.430 |
Why?
|
| Databases, Protein | 6 | 2020 | 54 | 0.430 |
Why?
|
| HIV Protease | 1 | 2014 | 22 | 0.430 |
Why?
|
| Protein Conformation | 6 | 2023 | 420 | 0.430 |
Why?
|
| Drug Design | 1 | 2015 | 183 | 0.420 |
Why?
|
| HIV Protease Inhibitors | 1 | 2014 | 24 | 0.420 |
Why?
|
| Molecular Dynamics Simulation | 4 | 2024 | 183 | 0.420 |
Why?
|
| Binding Sites | 5 | 2020 | 670 | 0.420 |
Why?
|
| Drug Resistance, Viral | 1 | 2014 | 67 | 0.410 |
Why?
|
| Mutation, Missense | 1 | 2014 | 88 | 0.410 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 36 | 0.410 |
Why?
|
| Algorithms | 5 | 2020 | 508 | 0.390 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2023 | 29 | 0.360 |
Why?
|
| HLA-A Antigens | 1 | 2011 | 7 | 0.360 |
Why?
|
| Humans | 27 | 2024 | 42163 | 0.350 |
Why?
|
| Immunotherapy | 3 | 2023 | 137 | 0.330 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2011 | 51 | 0.330 |
Why?
|
| Antigen Presentation | 1 | 2010 | 59 | 0.320 |
Why?
|
| Computational Biology | 4 | 2022 | 324 | 0.280 |
Why?
|
| HIV-1 | 1 | 2014 | 747 | 0.280 |
Why?
|
| Ligands | 3 | 2019 | 387 | 0.270 |
Why?
|
| Alleles | 4 | 2024 | 352 | 0.240 |
Why?
|
| Drug Discovery | 2 | 2018 | 106 | 0.240 |
Why?
|
| Structure-Activity Relationship | 4 | 2020 | 491 | 0.240 |
Why?
|
| Vimentin | 1 | 2024 | 38 | 0.220 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2024 | 53 | 0.220 |
Why?
|
| Hominidae | 1 | 2024 | 12 | 0.210 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2023 | 7 | 0.200 |
Why?
|
| Amino Acid Sequence | 5 | 2023 | 1188 | 0.200 |
Why?
|
| Sulfonamides | 1 | 2024 | 88 | 0.200 |
Why?
|
| Interferon-gamma | 1 | 2024 | 268 | 0.200 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2022 | 31 | 0.190 |
Why?
|
| Hepatitis C | 2 | 2015 | 138 | 0.180 |
Why?
|
| Computer Simulation | 3 | 2020 | 404 | 0.180 |
Why?
|
| Markov Chains | 1 | 2020 | 42 | 0.170 |
Why?
|
| Complement C3 | 1 | 2020 | 16 | 0.170 |
Why?
|
| Peptides, Cyclic | 1 | 2020 | 29 | 0.160 |
Why?
|
| Hepatitis E | 1 | 2019 | 3 | 0.160 |
Why?
|
| Hepatitis E virus | 1 | 2019 | 3 | 0.160 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 557 | 0.160 |
Why?
|
| Deuterium Exchange Measurement | 1 | 2018 | 2 | 0.150 |
Why?
|
| Complement C3b | 1 | 2018 | 3 | 0.150 |
Why?
|
| Multiprotein Complexes | 1 | 2019 | 55 | 0.150 |
Why?
|
| Antiviral Agents | 1 | 2020 | 189 | 0.140 |
Why?
|
| Interleukin-8 | 1 | 2018 | 74 | 0.140 |
Why?
|
| Cell Membrane | 1 | 2020 | 400 | 0.140 |
Why?
|
| Conserved Sequence | 2 | 2015 | 121 | 0.120 |
Why?
|
| Static Electricity | 2 | 2015 | 85 | 0.120 |
Why?
|
| Viral Vaccines | 1 | 2015 | 36 | 0.110 |
Why?
|
| Iduronidase | 1 | 2014 | 1 | 0.110 |
Why?
|
| Internet | 1 | 2015 | 234 | 0.110 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 135 | 0.100 |
Why?
|
| Viral Core Proteins | 1 | 2012 | 13 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 225 | 0.090 |
Why?
|
| Protein Isoforms | 2 | 2023 | 139 | 0.090 |
Why?
|
| Capsid Proteins | 1 | 2012 | 74 | 0.090 |
Why?
|
| Crystallography, X-Ray | 3 | 2019 | 285 | 0.090 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 87 | 0.090 |
Why?
|
| Immunity, Cellular | 1 | 2011 | 73 | 0.090 |
Why?
|
| Molecular Conformation | 1 | 2010 | 157 | 0.080 |
Why?
|
| Citrulline | 1 | 2024 | 14 | 0.060 |
Why?
|
| Clone Cells | 1 | 2023 | 50 | 0.050 |
Why?
|
| Genes, MHC Class I | 1 | 2023 | 14 | 0.050 |
Why?
|
| Mutation | 2 | 2020 | 1169 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2024 | 184 | 0.050 |
Why?
|
| Mammals | 1 | 2023 | 109 | 0.050 |
Why?
|
| Systems Biology | 1 | 2022 | 26 | 0.050 |
Why?
|
| Placenta | 1 | 2023 | 113 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2022 | 59 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 1058 | 0.050 |
Why?
|
| Prognosis | 1 | 2024 | 850 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 727 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 33 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2020 | 107 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2020 | 41 | 0.040 |
Why?
|
| Protein Stability | 1 | 2020 | 47 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 97 | 0.040 |
Why?
|
| Proline | 1 | 2020 | 39 | 0.040 |
Why?
|
| Hydrogen Bonding | 1 | 2020 | 143 | 0.040 |
Why?
|
| Lipid Bilayers | 1 | 2020 | 56 | 0.040 |
Why?
|
| HLA-A2 Antigen | 1 | 2019 | 4 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2020 | 114 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2019 | 26 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2019 | 94 | 0.040 |
Why?
|
| Animals | 3 | 2024 | 16695 | 0.040 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 81 | 0.040 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 86 | 0.040 |
Why?
|
| Phylogeny | 1 | 2022 | 740 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2023 | 722 | 0.040 |
Why?
|
| Pregnancy | 1 | 2023 | 1737 | 0.030 |
Why?
|
| Serotyping | 1 | 2015 | 37 | 0.030 |
Why?
|
| Hepatitis C Antibodies | 1 | 2015 | 10 | 0.030 |
Why?
|
| Dengue Vaccines | 1 | 2015 | 15 | 0.030 |
Why?
|
| Mucopolysaccharidosis I | 1 | 2014 | 1 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 206 | 0.030 |
Why?
|
| Dengue Virus | 1 | 2015 | 89 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2014 | 185 | 0.030 |
Why?
|
| Software Design | 1 | 2013 | 18 | 0.030 |
Why?
|
| Information Storage and Retrieval | 1 | 2013 | 35 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2013 | 74 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2012 | 271 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 638 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 1729 | 0.020 |
Why?
|
| Female | 1 | 2023 | 24018 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 6490 | 0.010 |
Why?
|